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Neuroticism predicts the impact 
of serotonin challenges on fear 
processing in subgenual anterior 
cingulate cortex
Bettina Hornboll1,2,8, Julian Macoveanu  1,2, Ayna Nejad1,3, James Rowe2,5,8, Rebecca Elliott6, 
Gitte M. Knudsen2,4,8, Hartwig R. Siebner1,7,8 & Olaf B. Paulson  1,2,4,8
The personality trait neuroticism is associated with increased vulnerability to anxiety and mood 
disorders, conditions linked with abnormal serotonin neurotransmission and emotional processing. 
The interaction between neuroticism and serotonin during emotional processing is however not 
understood. Here we investigate how individual neuroticism scores influence the neural response 
to negative emotional faces and their sensitivity to serotonergic tone. Twenty healthy participants 
performed an emotional face task under functional MRI on three occasions: increased serotonin tone 
following infusion of a selective serotonin reuptake inhibitor (SSRI), decreased serotonin tone following 
acute tryptophan depletion (ATD) protocol, and no serotonin challenge (control). During the task, 
participants performed a gender-discrimination task of neutral, fearful or angry facial expressions. 
Individual variations in neuroticism scores were associated with neural response of subgenual anterior 
cingulate cortex to fearful facial expressions. The association was however opposite under the two 
serotoninergic challenges. The fear-related response in this region and individual neuroticism scores 
correlated negatively during citalopram challenge and positively during ATD. Thus, neuroticism scores 
were associated with the relative impact of serotonin challenges on fear processing in subgenual 
anterior cingulate cortex. This finding may link to a neural mechanism for the variable therapeutic effect 
of SSRI treatment observed in clinical populations.
Impaired emotion-related processing has been associated with an increased risk for affective psychiatric illnesses, 
and facial expressions are linked to emotions and especially involved in social interactions1,2. Human and animal 
studies have provided cumulating evidence that serotonergic (5-hydroxytryptamine, 5-HT) neurotransmission 
plays a key role in processing and regulation of emotions)3. In healthy individuals, functional brain imaging has 
shown that serotonergic challenges alter the neural processing of facial expressions4–6, and may differentially 
modulate the neural response to different emotions such as anger and fear5,7,8. Whereas both fearful and angry 
faces imply threat, the type of threat is different for the two types of emotion. Where anger represents a more 
direct threat to the viewer and elicits avoidance behaviors, fear represents a more ambiguous threat and may at 
times elicit approach behaviors9.
In healthy individuals, acute (one dose) and extended treatment (up to seven days) with the selective serotonin 
reuptake inhibitor (SSRI) citalopram were shown to attenuate amygdala activation in response to negative facial 
expressions relative to neutral faces5,10–12 and to reduce attentional shifts away from aversive faces13. Acute SSRI 
was further shown to increase the neural response to happy but not to fearful faces in the amygdala14 whilst a 
facilitation in the recognition of fearful faces has also been found15. SSRI treatment with fluoxetine decreased the 
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activation level significantly in the sgACC and amygdala which has been found to be significantly higher in ado-
lescents with major depressed compared to normal controls for fearful compared to neutral facial expressions16.
In contrast to SSRI treatment, the ingestion of an amino acid mixture depleted of L-tryptophan, but contain-
ing large neutral amino acids yields a reversible decrease of central 5-HT synthesis. Termed Acute Tryptophan 
Depletion (ATD), it has shown to enhance the neural response to angry faces in a widespread neural network 
including frontal regions5, and to elicit a decreased recognition of fearful facial expressions in healthy women17.
Neuroticism is characterized by a tendency to worry and experience negative affect18. This personality trait 
has been associated with increased vulnerability to anxiety and mood disorders such as depression19. Positron 
emission imaging (PET) revealed an association between individual neuroticism scores and 5-HT2A receptor 
binding in frontolimbic areas, pointing towards a link between 5-HT signaling and neuroticism20,21. Functional 
brain imaging studies have further shown that the degree of neuroticism is associated with amygdala-prefrontal 
connectivity in response to viewing negative facial expressions22. Furthermore, neuroticism has been found to 
correlate positively with amygdala and sgACC activation during trials of high emotional conflict, compared with 
low emotional conflict trials23 and a higher sgACC activation has been found in response to fearful faces24.
The aim of the present study was to explore how the individual personality trait neuroticism predicts the 
impact of fluctuations in central 5-HT levels on emotional processing. To address this question we investigated 
a cohort from the Cimbi study (Center for Integrated Molecular Brain Imaging) where neuroticism correlations 
were planed from the outset. We assessed how the neuronal response to negative emotional stimulation is mod-
ulated by the interplay between 5-HT level and individual neuroticism scores. We studied a group of healthy 
subjects with blood oxygen level dependent (BOLD) functional MRI (fMRI). The fMRI measurements of the 
brain were performed in a state of decreased 5-HT transmission induced by ATD, a state of increased 5-HT 
transmission caused by the SSRI citalopram and a normal state without either 5-HT challenge. The task required 
subjects to discriminate the gender of faces with fearful, angry or neutral expressions. We chose these facial 
expressions because, although they may both imply threat, the behavioral response is different for the two facial 
expressions9 and numerous studies indicate a different neural response to angry vs. fearful faces (see review by 
Fusar-Poli7. Our principal focus is on the contrast between the global serotonergic changes induced by ATD and 
SSRI challenges, in terms of the interaction between the subject variable neuroticism and emotion processing. 
Based on previous studies of similar serotonergic challenges, we hypothesized that there may be no main effect of 
drug in a heterogeneous normative cohort.
Results
Behavioral data. The 3 × 3 ANOVA of the reaction time RT showed a main effect of emotion 
(F(1.9,40.8) = 25.5, p < 0.001), but no main effect of drug (F(1.8,37.7) = 0.91; p = 0.894) and no interaction 
between drug and emotion (F(2.7,56.2) = 0.568; p = 0.619). Mean RT was longer when subjects judged the gender 
of a fearful or angry face relative to a neutral face (F(37.7; 40.8) = 25.5; p < 0.001; Fig. 1). For the ATD challenge, 
mean RT was longer for angry than for neutral faces (t(21) = 2.68, p = 0.014) the same was true for fearful faces 
(fear: t(21) = 2.98, p = 0.007). Mean RT was longer for angry than neutral faces in the SSRI session (t(21) = 5.33, 
p < 0.001).
With respect to mean error rates, a 3 × 3 ANOVA with the factors 5-HT challenges (Control, ATD and SSRI) 
and emotions (angry, fear and neutral) showed a main effect of emotion (F(1.7, 37.7) = 34.89, p < 0.001) and drug 
(F(1.1, 23.9) = 6.12, p = 0.018), but no interaction between challenge and emotion. Simple t-tests revealed that 
error rates were overall decreased in SSRI challenge with a mean error rate of 2% compared to the control with a 
mean error rate of 4% for all three facial expressions (angry faces: p = 0.018, fearful faces: p = 0.026, neutral faces: 
p = 0.026). A comparable reduction in error rates was also found in the ATD condition with a mean error rate of 
2% (fearful faces: p = 0.013, neutral faces: p = 0.053; angry faces: p = 0.051).
The ANOVA of the POMS yielded a significant effect of time for Anger/Hostility with lower scores at the 
end of the scanning session as compared to pre-scanning baseline (F(12) = 6.98, p = 0.022) indicating that the 
subjects did not remain in a high arousal state throughout the scan. Importantly, there was no significant inter-
vention × time interaction in any of the reported mood states. Because the fMRI analyses focused on the differ-
ential effects of ATD and SSRI, we also set up a second ANOVA model with 2 × 3 factors including the two 5-HT 
interventions (ATD and SSRI) and time (arrival, before scan and after scan). Here we found a main effect of time, 
with a decrease in Vigor/Activity scores after both pharmacological interventions (F(22) = 6.61, p = 0.009), but 
neither a main effect of the type of intervention nor an intervention × time interaction for any of the mood states.
Biochemical data. Baseline prolactin levels correlated highly between challenges (r = 0.80, n = 19, 
p < 0.001). The ATD protocol reduced the plasma ratio of tryptophan by 75% (paired t-test: before M = 49.2, 
SD = 10.0; after M = 12.3, SD = 12.7; t(21) = 11.2, p < 0.001) consistent with reductions in central tryptophan 
bioavailability25,26. An ANOVA of prolactin levels revealed no main effect of drug (F < 1) or time within challenge 
from baseline to scanning (F1, 17 = 2.86, ns).
Neuroimaging data. Across all three conditions (ATD, SSRI, and control), the right inferior frontal gyrus as 
well as bilateral clusters of middle temporal gyrus stretching to the middle occipital gyrus and bilateral fusiform 
gyrus and amygdala showed increased activity for aversive faces relative to neutral faces (see Table 1 for peak 
coordinates). When separating the emotional faces, a similar pattern was found for activity that was greater for 
fearful than neutral faces (see Table 1 for peak coordinates). However, amygdala activity increases for angry faces 
compared to neutral faces were not seen (see Table 1 for peak coordinates). Neither the main effect of Challenge 
(SSRI and ATD) nor first level interaction between Challenge and Emotion (angry, fearful, and neutral) revealed 
any significant results.
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Impact of neuroticism on the responsiveness to drug challenges. Individual neuroticism scores 
modulated the effects of drug and emotion, and their interaction. Neuroticism was negatively associated with 
the impact of citalopram compared to ATD (SSRI > ATD) on the neural response of the right subgenual anterior 
cingulate cortex (sgACC) to fearful faces (Fig. 2). The higher the neuroticism score, the lower the sgACC activity 
increase with SSRI compared to the ATD condition (x, y, z = 9, 26, −4, Z = 5.0, pFWE = 0.015), No such relation-
ship was seen for angry faces. A post hoc analyses excluding two subjects who’s neuroticism score were more 
than 5 years from day of scanning, showed an increased correlation with sgACC activation (x, y, z = 9, 26, −4, 
pFWE = 0.009 and z = 5.1).
Post hoc analyses revealed a positive relationship between neuroticism scores and sgACC activity evoked by 
fearful facial expressions in the ATD challenge (Pearsons correlation; r = 0.551, p = 0.014). In contrast, we found 
a negative relationship between neuroticism scores and sgACC response to fearful faces in the SSRI challenge 
(Pearsons correlation; r = −0.611, p = 0.005).
Discussion
Our main finding is that personality trait neuroticism alters the effect of serotonin challenges on the neural 
response to fearful faces. The higher the neuroticism score, the lower the sgACC activity for SSRI compared to 
ATD condition (Fig. 2). This is driven by a negative correlation between neuroticism and activity levels in sgACC 
for fearful faces for the SSRI challenge, but a positive correlation for ATD. This suggests that SSRI treatment might 
be more effective in subjects scoring high in neuroticism, which is in accordance with previously published mate-
rial showing increased neuroticism scores to be associated with higher 5-HT2A receptor binding21. Furthermore, 
neuroticism scores has been found to increase functional connectivity of the amygdala with prefrontal regions27. 
Neuroticism is a risk factor for anxiety and mood disorders19, possibly associated with a circuitry involving the 
subgenual cortex together with parts of the orbitomedial PFC, amygdala, hippocampus, striatum and thalamus28. 
Furthermore, hypothalamus, raphe, and periaqueductal gray has been shown to be anatomically connected with 
the subgenual cortex in the monkey brain29, suggesting that abnormal synaptic connections between these areas 
and the subgenual cortex may contribute to abnormalities in emotion processing or regulation thereof. Hall 
et al.30 found activation in subgenual cortex to be correlated with the severity of depressive symptoms. A recent 
PET study found a positive correlation between serotonergic transporter (SERT) binding and cortisol awakening 
response (CAR) in subgenual cortex31. One might speculate that the neuroticism score may have been different 
if the NEO-PI-R test had been done during the pharmacological challenges. The NEO-PI-R test is known to be 
very stable throughout the life span32,33 and we find it highly unlikely that the scores would have been influenced 
Figure 1. Mean reaction time (RT) and error rates as recorded during the gender-judgment task based on facial 
expressions in the control, ATD and SSRI challenges. RT data are presented as mean ± standard error of the 
mean (SEM), error rates are presented as % correct responses ± standard error of the mean (SEM).
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during these short-lasting pharmacological challenges. In any case the NEO-PI-R tests in the present study rep-
resents the individual baseline personality scores.
Furthermore Madsen et al.27 did a post hoc psychophysiological interaction (PPI) between the amygdala and 
the sgACC as reported by Pezawas et al.34 for s-allele carriers showed a higher interaction. This increased inter-
action between the amygdala and the sgACC may be maladaptive under severe stress, potentially underlying the 
increased risk for developing depression within the context of stress, for s-alleles carriers35.
Synthesis of serotonin (5-HT) is dependent on the precursor L-tryptophan (TRP). We included only healthy 
subjects and found that neuroticism scores enhance the effect of ATD as compared to SSRI. This is in accordance 
with previous findings, e.g. Neumeister et al.36 showing that patients with major depressive disorder showed 
increased BOLD fMRI activation in the orbitofrontal cortex, anterior and posterior cingulate cortices, in response 
to ATD. A high proportion, 50–60% of patients with major depressive disorders experience depressive like symp-
toms in response to ATD, whereas healthy controls seem unaffected37. Further, ATD can induce a transient return 
of depressive symptoms in some patients with remitted major depressive disorders but not in controls36.
The overall difference between elevated levels of free serotonin due to SSRI, and the global lowering of ser-
otonin levels due to ATD did not reveal any main effect of drug when combining all facial expressions (neutral, 
angry, fear). However, in our previous study in the same group of subjects exploring the effects of 5-HT chal-
lenges on the neural response to emotional faces we have shown that an increase of serotonin levels due to acute 
citalopram infusion, abolished differential brain activity across aversive emotional expressions (angry and fear), 
whereas a reduction of serotonin levels due to ATD specifically enhanced the neural response towards angry 
faces, making it indistinguishable from the response to fearful faces5. While our current analyses did not reveal 
any significant main effect of either of the 5-HT challenges on neural activation compared to the control scan, 
we did find an increased accuracy following both ATD and SSRI interventions (Fig. 1). Furthermore, Grady et 
al.5, found a significant impact of ATD and SSRI on the selectivity on neural response to fearful faces, however 
the selectivity depended on the serotonin effect. An enhancement of the brains response to angry faces was seen 
with the ATD condition making the neural response similar to that of fearful faces, whereas the SSRI abolished 
differential brain responses across all three facial emotions (neutral, angry, fear). It is notable however, that our 
previous study implemented a multivariate data model in contrast with the univariate statistical analysis imple-
mented here. Although more recent studies has used dynamic video stimuli of face processing or social attention 
cues (e.g.38,39) our stimuli were all of static emotional facial expression. Static stimuli lent it self more easily to 
standardization for experimental studies, including timing and controlling for confounding variable in lower 
level physical features, which can be more challenging in dynamic stimuli. Also, we see a significant effect of task 
across drugs, dismissing the notion that our facial stimuli could be a confounding factor for the lack of significant 
findings when contrasting the SSRI and ATD challenges with the control scan.
We found no effect of 5-HT challenges on performance of the face task in terms of RT. Therefore, the effects 
observed in the brain can be attributed to the interactions of serotonin challenge and the neural processing of face 
emotions, and not to drug effect on behavior or mood.
Contrast Anatomical region
Cluster size 
(voxels) x y z Peak T Peak Z PFWE
Aversive 
faces > Neutral faces
Right middle temporal gyrus/middle occipital gyrus 402 51 −58 5 10.16 >8 <0.001
Right fusiform gyrus 85 42 −46 −16 9.02 >8 <0.001
Left fusiform gyrus 85 −42 −49 −16 8.70 >8 <0.001
Left middle occipital gyrus/middle temporal gyrus 368 −30 −94 −1 8.14 7.47 <0.001
Right amygdala 10 21 −7 −13 6.63 6.24 <0.001
Right inferior frontal gyrus 13 54 32 5 6.02 5.72 <0.001
Left amygdala 4 −21 −7 −16 5.66 5.41 0.0016
Angry 
faces > Neutral faces
Right middle temporal gyrus 184 51 −58 5 8.63 7.84 <0.001
Right fusiform gyrus 30 42 −46 −16 7.07 6.61 <0.001
Left fusiform gyrus 39 −42 −49 −16 7.05 6.60 <0.001
Left middle occipital gyrus/middle temporal gyrus 158 −48 −79 5 6.86 6.44 <0.001
Right middle occipital gyrus 38 27 −91 8 5.77 5.50 <0.001
Fearful 
faces > Neutral faces
Superior temporal gyrus 109 48 −40 8 7.34 6.83 <0.001
Right fusiform gyrus 24 42 −46 −19 6.83 6.42 <0.001
Left fusiform gyrus 36 −42 −46 −19 6.41 6.06 <0.001
Left middle occipital gyrus 27 −30 −94 −4 6.23 5.91 <0.001
Right amygdala 17 24 −13 −13 6.01 5.72 <0.001
Right middle occipital gyrus 23 27 −88 2 5.81 5.54 <0.001
Right middle temporal gyrus 7 48 −10 −16 5.63 5.38 0.0019
Left middle temporal gyrus 9 −51 −49 11 5.58 5.34 0.0024
Table 1. Peak Montral Neurogical Institute (MNI) coordinates and statistics of factorial model analysis of 
emotion across all challenges. The table reports XYZ coordinates, T and Z values, and p statistical value for each 
cluster peak, FWE corrected for multiple comparisons at the peak-level.
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Although participants reported themselves to be more angry or hostile on scanning days in general, POMS 
scores did not correlate with any of the activation measures and accordingly, we found no evidence that the 
changes of mood scores had any influence on the observed brain activity.
There are methodological and pharmacological limitations to the study. Due to differences in the protocols 
of the two 5-HT challenges, specifically the different routes of administering the challenges and the intervals 
between drug administration and scanning, the drug challenges were not double-blinded. A placebo control 
would have been advantageous in several respects, and prevent the need to consider placebo effects or effects of 
IV versus no manipulations. However, drug administration and blood samples were done by a trained medical 
laboratory technologist to ensure uniformity, whereas data collection were done by researchers. Additionally, as 
mentioned in the method section, when the study was designed, the study team and ethics committee agreed that 
a full placebo control of the oral ATD solution and the IV infusion for SSRI challenge, would be excessive for a 
within-subject design. Given the heterogeneity of cerebral 5-HT2A receptor binding and other genetic or person-
ality factors relevant to inhibition, a between-subjects design might have been compromised differently, by uncer-
tainty over the cause of differences between groups and imperfect matching. A cross-over design, albeit with a 
no-drug condition without blinded placebo IV/oral solutions was seen as the preferred option. Although subjects 
were made aware of potential side effects within the study, they were not made aware of the specific differences 
between the interventions or expected effects of these. Volunteers had no prior information about expected effects 
of the individual drugs; therefore, the task- and drug-specific observations cannot be readily accounted for by 
a simple placebo effect, a lack of blinding, or even an expectation or anticipation of the action of either SSRI or 
ATD. The only effects of the pharmacological challenges on mood, as obtained from the POMS, was on anger/
hostility scores, but these were not significantly related to any of the fMRI activity measures. This would appear to 
rule out any general influence of the drug challenges or scanning procedures on regional task-specific brain activ-
ity. Moreover, we did not see any differences in perfusion measures between drug challenges. Although we cannot 
rule out some influence of these procedural differences, we suggest that the uniqueness of this dataset, allowing 
for the assessment of different serotonin challenges on the brain’s response to emotion in the same individuals, 
outweighs these limitations.
In conclusion, both lowering and increasing the serotonergic tone of the brain increased the correlation with 
neuroticism scores. The personality trait neuroticism were positively associated with the relative impact of sero-
tonergic challenges on fear processing in subgenual anterior cingulate cortex, and it could be hypothesized that 
this could be a biomarker for neuroticism. This finding may represent a neural mechanism for the variable ther-
apeutic effect of SSRI treatment observed in clinical populations, and supports the hypothesis that serotonin and 
neuroticism are related through processing of threatening emotions.
Figure 2. (A) Statistical parametric map (SPM) showing changes in the subgenual cortex (sgACC) activation 
for fearful face expressions during the challenges. The SPM indicate changes in BOLD signal and are 
thresholded at p < 0.001 (uncorrected). (B) Shows the correlation between the individual neuroticism scores 
and the BOLD response in the sgACC for SSRI, control and ATD challenges.
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Methods
Participants. We recruited twenty-six right-handed healthy adults (17 males), from an already existing 
cohort of healthy subjects, who had all undergone psychological testing (NEO-PI-R) as well as PET imaging of 
the seronergic 5-HT2A receptor. Twenty participants (13 males) with a mean age of 31.2 ± 6.8 years were included 
in the final analysis. Three participants were excluded as they did not complete all three challenges of the study 
and three participants were excluded due to excessive movement during MRI scan acquisition. All participants 
were re-interviewed prior to inclusion to the present study. None of the participants reported a history of stimu-
lant abuse or other psychiatric or neurological disorders, nor had they ever been prescribed antipsychotic, anti-
depressant, or antianxiety medication. All participants had a normal neurological examination prior to inclusion.
Ethical approval and informed consent. Written informed consent was obtained prior to study inclusion 
according to the declaration of Helsinki II. The study was approved by the Ethics Committee of Copenhagen and 
Frederiksberg, Denmark (KF 01-2006-20).
Behavioral task. Upon arrival and immediately after scanning, participants completed a modified Danish 
version of the Profile of Mood States (POMS) questionnaire40 to assess current mood. For the ATD and SSRI 
sessions, participants also completed the POMS right before the MRI scan.
During fMRI, participants performed a gender judgment task on face stimuli taken from the Karolinska 
Directed Emotional Faces database41 all images used were static images of forward facing and direct gazed faces. 
Participants were instructed to button press with their right index or middle finger according to the gender of the 
face as quickly as possible. The face stimuli were unmasked color photographs shown from a frontal perspective 
with neutral, fearful or angry expressions. The images were presented in the middle of the screen for 1800 ms, 
with a 200 ms inter-trial-interval (ITI).
We employed a mixed fMRI design with alternating emotional blocks (NEUTRAL-ANGRY-NEUTRAL- 
FEARFUL-NEUTRAL…) showing male and female faces in equal proportion. Each block comprised of six 
events, which were pseudo-randomly intermixed: three to five face stimuli (average of four), and one to three 
(average of two) null events (fixation cross). In total, 32 blocks of neutral, and 16 blocks of each fear and angry 
faces, were presented over two fMRI runs separated by a short break. Each neutral face stimulus was presented 
twice and aversive face stimuli were presented once. Stimulus presentation and response recordings were per-
formed using E-prime 1.2 (Psychological Software Tools, Pittsburgh, PA, USA).
Serotonergic challenges. Participants took part in four experimental days with the challenges: SSRI, ATD, 
ketanserin, and a control. The focus on this particular part of the study is on the global effect of serotonin level 
in the brain, increased following SSRI and decreased following ATD. As ketanserin specially blocks the 5-HT2A 
receptor the results from the receptor blocking with ketanserin has been reported elsewhere6. Each challenge 
was performed on four different days at least one week apart. The order of the challenges was randomized and 
counterbalanced across participants (Table 2). All MRI measurements were carried out between noon and 6 pm. 
Participants were informed about common potential side effects of the challenges, but not about any expected 
behavioral effects of the challenges. Because of considerable differences in the mode of administration across the 
challenges, and after advice from the Ethics Committee, a double placebo regimen was not used for the study pro-
tocol. However, apart from the pharmacological manipulation and blood sampling, the experimental procedures 
were the same.
The SSRI challenge was initiated prior to fMRI acquisition with a two hour intravenous infusion of citalopram 
at a dose of 20 mg/h to ensure a stable and sufficient transporter blocking throughout the MRI scan (others have 
used shorter infusion times, see e.g.11,42. The initial infusion was followed by a maintenance dose during fMRI 
acquisition of 8 mg/h (~50 mg in total).
For the ATD challenge, upon arrival on the scanning day, subjects ingested within a maximum period of 
10 minutes 75 g tryptophan-free powdered mixture of essential and non-essential amino acids dissolved in water 
(XLYS, TRY Glutaridon, SHS International Ltd) after having kept a low protein diet the day before. fMRI acquisi-
tion was performed five hours after ingestion.
To assess a biological effect of the serotonergic challenge serum prolactin blood samples were collected three 
times; before challenge (citalopram or ATD administration), right before scanning start and right after the MRI 
scan.
For the control condition, subjects were taken directly to the scanner without any prior waiting time or (pla-
cebo) interventions.
Neuroticism. The Revised NEO Personality Inventory (NEO-PI-R) were obtained on average 2.2 ± 2.2, max 
5.8 years prior to the fMRI scans, as an individual neuroticism scores, which were the main variable of interest. 
The test scores are considered stable in adult life, although some long term decline in scores have been seen to 
occur with age29,32,33. However considering the relative short time (max. 5.8 years) between NEO-PI-R testing 
and fMRI we considered it redundant to do a time correction on the NEO-PI-R data, and as such the NEO-PI-R 
was not redone on our included subject on a time closer to the fMRI scans. To further support the use of the 
NEO-PI-R tests done earlier we reanalyzed the data excluding the two subjects with a time interval NEO-PI-R 
test to scan of more than five years. This resulted in an even stronger correlation to the sgACC (Z = 5.1 and 
pfwe = 0.009 instead of Z = 5.0 and pFWE = 0.015 as reported in result section above).
The NEO-PI-R is based on the five-factor model of personality and provides metrics for broad personality 
dimensions of extraversion, agreeableness, conscientiousness, neuroticism, and openness to experience. It is a 
psychological self-reported personality inventory, which consists of 240 items. Participants indicated on a scale 
from 1 to 5 how well each statement fits his or her personality. The inventory was developed to test adults without 
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overt psychopathology32,33. Participants completed the Danish version of the 240-item NEO-PI-R self-report 
personality questionnaire. The Danish translation of the NEO-PI-R has been psychometrically evaluated and 
normed in a standardization sample of 600 subjects43,44.
Each factor score is derived by adding the scores from assessment of six personality traits (facets) of each of 
the five personality factors and each trait score is derived by adding the scores on eight items in 0–4 Likert format.
Magnetic resonance imaging. MR images were acquired on a 3 T Trio scanner with an eight-channel head 
array coil (Siemens, Erlangen, Germany). Blood oxygen level dependent (BOLD) fMRI using a T2*-weighted gra-
dient echo spiral echo-planar (EPI) sequence with a repetition time of 2.5 s, echo time of 26 ms, flip angle of 76°, 
and 41 slices with a slice thickness of 3 mm and 25% gap between slices. The EPI sequence was optimized for sig-
nal recovery in orbitofrontal cortex by tilting slice orientation from a transverse toward a coronal orientation by 
about 30° and the use of a preparation gradient pulse45. A total of 156 whole-brain volumes were acquired in each 
of the two fMRI sessions (total 13 min). Physiological measurements of pulse (monitored with an infrared finger 
clip) and respiration (monitored with a chest belt) were obtained during fMRI acquisition. B0 field maps were 
acquired either before or after fMRI acquisition (TR = 488 ms; TE1 = 5.19 ms, TE2 = 7.65 ms; flip angle = 60°; dis-
tance factor = 25%; FOV = 240 mm; 41 slices; slice thickness = 3 mm). We additionally acquired a high-resolution 
3D structural brain scan using a T1-weighted spin echo sequence (TI/TE/TR = 800/3.93/1540 ms, flip angle 9°, 
1 × 1 × 1 mm isotropic resolution).
Analysis of the fMRI data. On visual inspection of the fMRI data, artifacts (possibly due to radio frequency 
interferences) were identified in some slices for seven of the fMRI scan sessions (over six subjects). We therefore 
applied to these seven sets of functional images the slice repair utility within the ArtRepair toolbox for SPM12 
(http://spnl.stanford.edu/tools/ArtRepair), which automatically detects bad slices and repairs by interpolation 
from slices of previous and subsequent volumes. In order to correct for B0 field inhomogeneities, the acquired 
B0 fieldmap was used to create a voxel displacement map (VDM) with the Fieldmap toolbox integrated within 
SPM12. The resulting VDM was used to unwarp the functional images during the realignment procedure for 
each session. Realignment was to the first functional volume and a mean functional image was created. The mean 
functional image was co-registered to the T1-weighted anatomical image and co-registration parameters were 
applied to all other functional images. The T1-weighted anatomical image was segmented using standard tissue 
priors and normalized to MNI (Montreal Neurological Institute) stereotactic space. The resulting deformation 
field image of the non-linear warping parameters for normalization from native space to MNI template space was 
then applied to the functional images. Lastly, normalized functional images were smoothed with a 6 mm Gaussian 
kernel.
The functional data from all three scanning days were analyzed in a single event-related general linear model 
as separate sessions. Onsets of each task event were modeled as stick functions convolved with SPM’s canonical 
hemodynamic response function with separate regressors for Neutral, Angry, and Fear. Each individual’s realign-
ment parameters and their derivatives were modeled to account for head movement and subsequent spin effects46 
Physiological noise was modeled with RETROICOR47,48 to obtain six respiration and four pulse regressors. The 
first-level contrasts for each challenge day’s Neutral, Angry, and Fear events were entered into a second-level 
flexible factorial design to investigate the within-group effects of challenge and emotional face processing. There 
were three factors modeled: “Subject”, “type of pharmacological Challenge” (3 levels: ATD, SSRI, and control), and 
“Emotion” (3 levels: fearful, angry and neutral). In order to verify that subjects responded to emotional stimuli, we 
ran within-group t-contrasts for Fear > Neutral, Anger > Neutral, and Aversive (Fear and Anger) > Neutral. We 
Scanning day: 
Subject # 1st 2nd 3rd 4th
1 Control Ket SSRI ATD
2 ATD Control Ket SSRI
3 SSRI ATD Control Ket
4 Ket SSRI ATD Control
5 Control Ket SSRI ATD
6 ATD Control Ket SSRI
7 SSRI ATD Control Ket
8 Ket SSRI ATD Control
9 Control Ket SSRI ATD
10 ATD Control Ket SSRI
11 SSRI ATD Control Ket
12 Ket SSRI ATD Control
13 Control Ket SSRI ATD
14 ATD Control Ket SSRI
15 SSRI ATD Control Ket
16 Ket SSRI ATD Control
17 Control Ket SSRI ATD
Table 2. Counterbalanced order of scanning days for the 17 participants included in the study.
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tested F-contrasts for the main effect of Challenge and the interaction effects of Emotion x Challenge. Significant 
findings in these were followed up, post-hoc, by their respective t-contrasts.
In the analysis of association with neuroticism scores, we ran one-sample t-tests of contrasts between chal-
lenges for aversive faces, i.e. ATD > control, SSRI > control, and SSRI > ATD for the fear events and for the anger 
events, separately. Neuroticism scores for each individual were entered as a covariate of interest. These analyses 
were conducted on 19 participants since neuroticism data was lacking for one participant.
In all tests, the significance threshold was set to a whole-brain p < 0.05, corrected for multiple comparisons 
with peak-level family wise error (FWE) correction, which is a conservative threshold according to recent dis-
cussions in the field49.
Analysis of task performance. Behavioral data were analyzed using SPSS (version 20, Chicago, Illinois, 
USA). Individual scores on mood questionnaires were analyzed using a three-way repeated measures ANOVA 
with the within-subject factors challenge (ATD, SSRI, control), mood factors of the POMS (6 levels), and time of 
assessment relative to fMRI (arrival, before and after scan). Reaction time changes were assessed using a two-way 
repeated measures ANOVA with within-subject factors challenge (ATD, SSRI, control) and emotion of the face 
stimuli (neutral, angry, fear). The Greenhouse-Geisser method was used to correct for non-sphericity when 
appropriate. Conditional on significant F-values in the ANOVA, post-hoc paired t-tests were performed. Error 
rates were analyzed using nonparametric Wilcoxon signed-rank tests, comparing each facial expression from 
the control scan with the same facial expression from the relative drug challenge. Behavioral data are given as 
mean ± standard deviation.
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